David R W Jayne

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi request reprint Current management of lupus nephritis: popular misconceptions
    D Jayne
    Adenbrooke s Hospital, Cambridge, UK
    Lupus 16:217-20. 2007
  2. doi request reprint Maintaining remission in a patient with vasculitis
    Oliver Flossmann
    Vasculitis and Lupus Unit, Addenbrooke s Hospital, Cambridge, UK
    Nat Clin Pract Rheumatol 4:499-504. 2008
  3. ncbi request reprint Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
    Rachel B Jones
    Vasculitis and Lupus Clinic, Renal Unit, Addenbrooke s Hospital, Cambridge, United Kingdom
    N Engl J Med 363:211-20. 2010
  4. doi request reprint New-generation therapy for ANCA-associated vasculitis
    David Jayne
    Department of Medicine, University of Cambridge, Cambridge, CB22QQ, UK
    Clin Exp Nephrol 17:694-6. 2013
  5. pmc Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial
    Michael Walsh
    Departments of Medicine and Clinical Epidemiology and Biostatistics, Marian Wing, Division of Nephrology, McMaster University, St, Joseph s Hospital, 50 Charlton Ave East, Hamilton, ON L8S 4A6, Canada
    Trials 14:73. 2013
  6. doi request reprint Treating vasculitis with conventional immunosuppressive agents
    David Jayne
    Vasculitis and Lupus Clinic, Addenbrooke s Hospital, Cambridge, UK
    Cleve Clin J Med 79:S46-9. 2012
  7. pmc Membranoproliferative glomerulonephritis
    Bassam Alchi
    Renal Unit, Addenbrooke s Hospital, Cambridge, CB2 0QQ, UK
    Pediatr Nephrol 25:1409-18. 2010
  8. doi request reprint Review article: Progress of treatment in ANCA-associated vasculitis
    David Jayne
    Addenbrooke s Hospital, Cambridge, UK
    Nephrology (Carlton) 14:42-8. 2009
  9. doi request reprint The diagnosis of vasculitis
    David Jayne
    Addenbrooke s Hospital, Renal Unit, Cambridge, UK
    Best Pract Res Clin Rheumatol 23:445-53. 2009
  10. ncbi request reprint Part 3: Newer therapies for ANCA-associated vasculitis
    D Jayne
    Renal Unit, Addenbrooke s Hospital, Cambridge, UK
    Clin Exp Rheumatol 25:S77-9. 2007

Detail Information

Publications46

  1. ncbi request reprint Current management of lupus nephritis: popular misconceptions
    D Jayne
    Adenbrooke s Hospital, Cambridge, UK
    Lupus 16:217-20. 2007
    ..Regimens involving maintenance phases have been developed, but uncertainty remains about the risk of flares and how they can be predicted. The optimum duration of treatment has yet to be determined...
  2. doi request reprint Maintaining remission in a patient with vasculitis
    Oliver Flossmann
    Vasculitis and Lupus Unit, Addenbrooke s Hospital, Cambridge, UK
    Nat Clin Pract Rheumatol 4:499-504. 2008
    ..Further treatment with cyclophosphamide achieved a second remission, but the patient relapsed again despite remission-maintaining treatment with mycophenolate mofetil...
  3. ncbi request reprint Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
    Rachel B Jones
    Vasculitis and Lupus Clinic, Renal Unit, Addenbrooke s Hospital, Cambridge, United Kingdom
    N Engl J Med 363:211-20. 2010
    ..Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens...
  4. doi request reprint New-generation therapy for ANCA-associated vasculitis
    David Jayne
    Department of Medicine, University of Cambridge, Cambridge, CB22QQ, UK
    Clin Exp Nephrol 17:694-6. 2013
    ..Targets for therapy currently in development in ANCA associated vasculitis include blockade of complement and pro-inflammatory cytokines, and inhibition of T cell co-stimulation. ..
  5. pmc Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial
    Michael Walsh
    Departments of Medicine and Clinical Epidemiology and Biostatistics, Marian Wing, Division of Nephrology, McMaster University, St, Joseph s Hospital, 50 Charlton Ave East, Hamilton, ON L8S 4A6, Canada
    Trials 14:73. 2013
    ..A randomized study of both plasma exchange and glucocorticoids is required to evaluate plasma exchange and oral glucocorticoid dosing in patients with AAV...
  6. doi request reprint Treating vasculitis with conventional immunosuppressive agents
    David Jayne
    Vasculitis and Lupus Clinic, Addenbrooke s Hospital, Cambridge, UK
    Cleve Clin J Med 79:S46-9. 2012
    ..Individualized evaluation of risk and treatment selection will help maximize effectiveness and minimize toxicity...
  7. pmc Membranoproliferative glomerulonephritis
    Bassam Alchi
    Renal Unit, Addenbrooke s Hospital, Cambridge, CB2 0QQ, UK
    Pediatr Nephrol 25:1409-18. 2010
    ..Improvement in renal outcomes largely relies on the evaluation of more selective agents in carefully controlled studies...
  8. doi request reprint Review article: Progress of treatment in ANCA-associated vasculitis
    David Jayne
    Addenbrooke s Hospital, Cambridge, UK
    Nephrology (Carlton) 14:42-8. 2009
    ..These have led to consensus recommendations on how AAV should be treated. Many newer agents are currently under evaluation which have the potential to improve AAV outcomes in the future...
  9. doi request reprint The diagnosis of vasculitis
    David Jayne
    Addenbrooke s Hospital, Renal Unit, Cambridge, UK
    Best Pract Res Clin Rheumatol 23:445-53. 2009
    ..When the diagnosis remains uncertain, observation over time, repeat investigation and a therapeutic trial may improve the probability of the diagnosis or identify an alternative disease...
  10. ncbi request reprint Part 3: Newer therapies for ANCA-associated vasculitis
    D Jayne
    Renal Unit, Addenbrooke s Hospital, Cambridge, UK
    Clin Exp Rheumatol 25:S77-9. 2007
  11. ncbi request reprint Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis
    David R W Jayne
    Department of Medicine, Addenbrooke s Hospital, Cambridge, UK
    J Am Soc Nephrol 18:2180-8. 2007
    ..Patient survival and severe adverse event rates were similar in both groups...
  12. ncbi request reprint How to induce remission in primary systemic vasculitis
    David Jayne
    Nephrology and Vasculitis, Box 118, Renal Unit, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK
    Best Pract Res Clin Rheumatol 19:293-305. 2005
    ..Their correct evaluation and integration with current regimens to improve long-term outcome is the major challenge in clinical vasculitis research today...
  13. ncbi request reprint Autologous stem cell transplantation for systemic lupus erythematosus
    David Jayne
    Department of Medicine, Addenbrooke s Hospital, Cambridge, UK
    Lupus 13:168-76. 2004
    ..The safety of this procedure is likely to be improved by patient selection and choice of conditioning regimen. The return of disease activity in one-third of patients might be reduced by long-term immunosuppressive therapy post-ASCT...
  14. ncbi request reprint The clinical features and pathology of vasculitis associated with anti-myeloperoxidase autoantibodies
    David Jayne
    Vasculitis and Lupus Clinic, Addenbrooke s Hospital, Cambridge, UK
    Jpn J Infect Dis 57:S16-7. 2004
    ..An understanding of the biology of MPO and its involvement in the pathogenesis of vasculitis is of importance in understanding the pathogenesis of vasculitis and the development of newer therapies...
  15. ncbi request reprint Conventional treatment and outcome of Wegener's granulomatosis and microscopic polyangiitis
    David R W Jayne
    Department of Medicine, Addenbrooke s Hospital, Cambridge, UK
    Cleve Clin J Med 69:SII110-5. 2002
  16. ncbi request reprint Stem cell transplantation in systemic lupus erythematosus
    David Jayne
    Renal Unit, Addenbrookes Hospital, Box 157, Cambridge CB2 2QQ, UK
    Best Pract Res Clin Haematol 17:291-304. 2004
    ..With the availability of other alternative therapies in refractory disease, there needs to be a clear demonstration of the benefits of HSCT from current randomized trials...
  17. doi request reprint Challenges in the management of microscopic polyangiitis: past, present and future
    David Jayne
    Renal Unit, Department of Medicine, Addenbrooke s Hospital, Cambridge, UK
    Curr Opin Rheumatol 20:3-9. 2008
    ..The presentation and management of renal involvement in microscopic polyangiitis is discussed, with emphasis on prognosis and outcomes. Potential roles of newer therapies are reviewed...
  18. doi request reprint Role of rituximab therapy in glomerulonephritis
    David Jayne
    Renal Medicine, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
    J Am Soc Nephrol 21:14-7. 2010
    ..The toxicity and infective risk of B cell-targeted agents in renal disease needs to be determined as well as their optimal dosing in combination with conventional agents...
  19. pmc A CD8+ T cell transcription signature predicts prognosis in autoimmune disease
    Eoin F McKinney
    Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Institute for Medical Research, Addenbrooke s Hospital, Cambridge, UK
    Nat Med 16:586-91, 1p following 591. 2010
    ..These subgroups, which are also found in the normal population and can be identified by measuring expression of only three genes, raise the prospect of individualized therapy and suggest new potential therapeutic targets in autoimmunity...
  20. doi request reprint A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis
    Rachel B Jones
    Renal Unit, Addenbrooke s Hospital, Cambridge, UK
    Arthritis Rheum 60:2156-68. 2009
    ..This permitted comparison of rituximab dosing regimens, the value of continuing immunosuppression, and investigation of ANCA and B cell levels as re-treatment biomarkers...
  21. doi request reprint Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis
    Rona M Smith
    Addenbrooke s Hospital, Cambridge, UK
    Arthritis Rheum 64:3760-9. 2012
    ..However, further relapse is common, and maintenance strategies are required. The aim of this study was to reduce relapse rates using a fixed-interval rituximab re-treatment protocol...
  22. doi request reprint Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis
    Mary Jane C J Guerry
    Vasculitis and Lupus Unit, Box 57, Department of Medicine, Addenbrooke s Hospital, Hills Road, Cambridge CB2 0QQ, UK
    Rheumatology (Oxford) 51:634-43. 2012
    ..To perform a literature review and develop recommendations for the use of rituximab in ANCA-associated vasculitis...
  23. ncbi request reprint Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study
    Anthony D Booth
    Department of Medicine, Addenbrookes s Hospital, Cambs, UK
    Am J Kidney Dis 41:776-84. 2003
    ..Renal involvement is frequently present in antineutrophil cytoplasmic autoantibody (ANCA)-associated systemic vasculitis and is an important cause of end-stage renal failure (ESRF)...
  24. pmc The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
    Helena Marco
    Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, UK
    BMC Musculoskelet Disord 15:178. 2014
    ..CD20 is not expressed on mature plasma cells and accordingly rituximab does not have immediate effects on immunoglobulin levels. However, after rituximab some patients develop hypogammaglobulinaemia...
  25. pmc Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis
    Paul A Lyons
    Department of Medicine, Cambridge Institute for Medical Research, Addenbrooke s Hospital, Hills Road, Cambridge CB2 0XY, UK
    Ann Rheum Dis 69:1208-13. 2010
    ....
  26. doi request reprint Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial
    Thomas F Hiemstra
    University of Cambridge and Lupus and Vasculitis Unit, Addenbrookes Hospital, Cambridge, England
    JAMA 304:2381-8. 2010
    ..Current remission maintenance therapies for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are limited by partial efficacy and toxicity...
  27. doi request reprint Antineutrophil cytoplasm antibody-associated vasculitis: recent developments
    Shunsuke Furuta
    Lupus and Vasculitis Clinic, Addenbrooke s Hospital, Cambridge University Hospitals, Cambridge, UK
    Kidney Int 84:244-9. 2013
    ..Long-term outcomes following current treatment strategies have been determined and increased risks for cardiovascular and malignant disease reported. ..
  28. doi request reprint Biological therapy for lupus nephritis-tribulations and trials
    Rona M Smith
    Department of Renal Medicine, Addenbrooke s Hospital, Hills Road, Cambridge CB2 0QQ, UK
    Nat Rev Rheumatol 6:547-52. 2010
    ..The complexities of clinical trials in lupus nephritis have impeded the demonstration of the efficacy of new agents, but if these difficulties can be overcome, there is a real chance that outcomes in lupus nephritis will improve...
  29. ncbi request reprint Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis
    Maria Koukoulaki
    Vasculitis and Lupus Clinic, Addenbrooke s Hospital, Cambridge, UK
    Nephron Clin Pract 102:c100-7. 2006
    ..Mycophenolate mofetil (MMF) is an immune suppressive initially introduced for the prevention of solid organ allograft rejection that is increasingly used in autoimmune conditions, including vasculitis...
  30. ncbi request reprint Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab
    Maria Koukoulaki
    The Vasculitis and SLE Unit, Department of Medicine, University of Cambridge School of Clinical Medicine, UK
    Nephrol Dial Transplant 20:213-6. 2005
  31. ncbi request reprint Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab
    Menna R Clatworthy
    Lupus and Vasculitis Clinic, Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK
    Am J Kidney Dis 47:680-2. 2006
    ..The hemophilia followed a relapsing course under oral corticosteroid therapy, but B-cell depletion with anti-CD20 monoclonal antibody (rituximab) was effective in inducing a prolonged remission...
  32. doi request reprint B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study
    M Martinez Del Pero
    Department of Otolaryngology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    Clin Otolaryngol 34:328-35. 2009
    ..This study aimed to evaluate the response of refractory Wegener's granulomatosis affecting the ear, nose and throat and granulomatous eye disease to B-cell depletion with rituximab...
  33. pmc Progress in treatment of ANCA-associated vasculitis
    Rona M Smith
    Department of Renal Medicine, Addenbrooke s Hospital, Hills Road, Cambridge CB20QQ, UK
    Arthritis Res Ther 14:210. 2012
    ..As rare diseases, treatment advances in vasculitis depend on international collaborative research networks both to establish an evidence base for newer agents and to develop recommendations for patient management...
  34. pmc Genetically distinct subsets within ANCA-associated vasculitis
    Paul A Lyons
    Cambridge Institute for Medical Research, and Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke s Hospital, Cambridge, United Kingdom
    N Engl J Med 367:214-23. 2012
    ..Its cause is unknown, and there is debate about whether it is a single disease entity and what role ANCA plays in its pathogenesis. We investigated its genetic basis...
  35. doi request reprint Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid
    Thomas F Hiemstra
    Lupus and Vasculitis Unit, Addenbrookes Hospital, Cambridge, UK
    Nephron Clin Pract 116:c1-10. 2010
    ....
  36. ncbi request reprint Immunotherapy for autoimmune and inflammatory renal diseases
    Anthony D Booth
    Department of Renal Medicine Box 118, Addenbrooke s Hospital, Hills Rd, Cambridge, CB2 2QQ, UK
    Expert Opin Biol Ther 3:487-500. 2003
    ..Larger, randomised comparisons to standard therapy are needed along with assessment of long-term efficacy and safety...
  37. ncbi request reprint Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)
    M Walsh
    Vasculitis Clinic, Box 118, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Ann Rheum Dis 67:1322-7. 2008
    ..Humanised monoclonal anti-CD52 antibodies (alemtuzumab, CAMPATH-1H) selectively deplete lymphocytes. We present long-term follow-up results of patients with relapsing/refractory AASV treated with CAMPATH-1H...
  38. ncbi request reprint Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future
    M Walsh
    Department of Renal Medicine, Addenbrooke s Hospital, Cambridge, United Kingdom
    Kidney Int 72:676-82. 2007
    ..Future randomized control trials and long-term follow-up studies are required to confirm the role of RTX and other B-cell targeting therapies in AASV and SLE...
  39. doi request reprint Anaemia, weight loss, and round shadows in the lungs
    Avnesh S Thakor
    Department of Renal Medicine, Addenbrooke s Hospital, University of Cambridge, Cambridge, UK
    Lancet 371:88. 2008
  40. ncbi request reprint Update on the European Vasculitis Study Group trials
    D Jayne
    Senior Lecturer in Renal Medicine, Renal Unit, St Helier Hospital, Carshalton, Surrey, UK
    Curr Opin Rheumatol 13:48-55. 2001
    ..The established infrastructure and accumulated database are well placed to facilitate testing of newer therapeutic strategies in the future...
  41. ncbi request reprint Pulmonary renal syndrome: a 4-year, single-center experience
    Hugh Gallagher
    SW Thames Renal Unit, St Helier Hospital, Carshalton, Surrey, UK
    Am J Kidney Dis 39:42-7. 2002
    ..Cyclophosphamide-associated neutropenia and infection were frequent contributors to death, and less toxic alternatives may improve outcome in PRS...
  42. ncbi request reprint Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups
    Herbert A Hauer
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Kidney Int 61:80-9. 2002
    ..The possible differences in histopathology are investigated in this study...
  43. ncbi request reprint Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients
    Herbert A Hauer
    Department of Pathology and Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands
    Kidney Int 62:1732-42. 2002
    ....
  44. ncbi request reprint Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement
    Robert A F de Lind van Wijngaarden
    Leiden University Medical Center, Department of Pathology, Postbus 9600, 2300 RC Leiden, The Netherlands
    J Am Soc Nephrol 17:2264-74. 2006
    ..36, P = 0.01). Normal glomeruli were a positive predictor of dialysis independence and improved renal function after 12 mo, indicating that the unaffected part of the kidney is vital in determining renal outcome...
  45. ncbi request reprint Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis
    Robert A F de Lind van Wijngaarden
    Department of Pathology, Leiden University Medical Center, Albinusdreef 2, Leiden, Netherlands
    J Am Soc Nephrol 18:2189-97. 2007
    ..Even with ominous histologic findings, the chance of renal recovery exceeds the chance of therapy-related death when these patients are treated with plasma exchange as adjunctive therapy...
  46. ncbi request reprint Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis
    Kirsten de Groot
    Medical School Hannover, Germany
    Arthritis Rheum 52:2461-9. 2005
    ..This unblinded, prospective, randomized, controlled trial was undertaken to determine whether methotrexate (MTX) could replace CYC in the early treatment of AASV...